Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.

GKOS

Glaukos (GKOS)

Glaukos Corporation
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:GKOS
DateHeureSourceTitreSymboleSociété
14/06/202413h10Edgar (US Regulatory)Form 8-K - Current reportNYSE:GKOSGlaukos Corporation
14/06/202413h00Business WireGlaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common StockNYSE:GKOSGlaukos Corporation
06/06/202401h35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:GKOSGlaukos Corporation
03/06/202422h25Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:GKOSGlaukos Corporation
30/05/202422h45Edgar (US Regulatory)Form SD - Specialized disclosure reportNYSE:GKOSGlaukos Corporation
28/05/202413h00Business WireGlaukos Announces Participation in Upcoming Investor ConferencesNYSE:GKOSGlaukos Corporation
01/05/202422h05Business WireGlaukos Announces First Quarter 2024 Financial ResultsNYSE:GKOSGlaukos Corporation
16/04/202422h05Business WireGlaukos Announces the Release of its 2023 Sustainability ReportNYSE:GKOSGlaukos Corporation
10/04/202413h00Business WireGlaukos to Release First Quarter 2024 Financial Results after Market Close on May 1NYSE:GKOSGlaukos Corporation
03/04/202413h00Business WireGlaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)NYSE:GKOSGlaukos Corporation
01/04/202413h00Business WireGlaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual MeetingNYSE:GKOSGlaukos Corporation
05/03/202402h07Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NYSE:GKOSGlaukos Corporation
23/02/202423h23Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NYSE:GKOSGlaukos Corporation
21/02/202422h05Business WireGlaukos Announces Fourth Quarter and Full Year 2023 Financial ResultsNYSE:GKOSGlaukos Corporation
13/02/202423h41Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NYSE:GKOSGlaukos Corporation
31/01/202413h00Business WireGlaukos to Release Fourth Quarter and Full Year 2023 Financial Results after Market Close on February 21NYSE:GKOSGlaukos Corporation
09/01/202413h00Business WireGlaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Net Sales and Reaffirms 2024 Revenue GuidanceNYSE:GKOSGlaukos Corporation
20/12/202313h00Business WireGlaukos Announces Participation in the J.P. Morgan Healthcare ConferenceNYSE:GKOSGlaukos Corporation
14/12/202314h04Dow Jones NewsFDA Approves Glaukos' New Drug Application for iDose TRNYSE:GKOSGlaukos Corporation
14/12/202313h00Business WireGlaukos Announces FDA Approval of iDose® TR (travoprost intracameral implant)NYSE:GKOSGlaukos Corporation
07/11/202313h00Business WireGlaukos Announces Participation in Stifel Healthcare ConferenceNYSE:GKOSGlaukos Corporation
01/11/202321h38Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:GKOSGlaukos Corporation
01/11/202321h05Business WireGlaukos Announces Third Quarter 2023 Financial ResultsNYSE:GKOSGlaukos Corporation
31/10/202312h00Business WireGlaukos Technologies Featured in Numerous Scientific Abstracts at the 2023 American Academy of Ophthalmology Annual MeetingNYSE:GKOSGlaukos Corporation
11/10/202313h00Business WireGlaukos to Release Third Quarter 2023 Financial Results after Market Close on November 1, 2023NYSE:GKOSGlaukos Corporation
23/08/202313h00Business WireGlaukos Announces Participation in Wells Fargo Healthcare ConferenceNYSE:GKOSGlaukos Corporation
02/08/202322h05Business WireGlaukos Announces Second Quarter 2023 Financial ResultsNYSE:GKOSGlaukos Corporation
17/07/202313h00Business WireGlaukos Enters into a Collaboration and Marketing Agreement with Radius XR, Inc.NYSE:GKOSGlaukos Corporation
12/07/202313h00Business WireGlaukos to Release Second Quarter 2023 Financial Results after Market Close on August 2, 2023NYSE:GKOSGlaukos Corporation
28/06/202322h21Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NYSE:GKOSGlaukos Corporation
 Showing the most relevant articles for your search:NYSE:GKOS